Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 18, 2018 - Issue 9
Submit an article Journal homepage
1,841
Views
6
CrossRef citations to date
0
Altmetric
Editorial

Ustekinumab in psoriatic arthritis: need for studies from real-world evidence

Rubén QueiroRheumatology Division, Hospital Universitario Central de Asturias (HUCA), Oviedo, SpainCorrespondence[email protected]
View further author information
&
Pablo Coto-SeguraDermatology Division, Hospital Alvarez Buylla, Mieres, Asturias, SpainView further author information
Pages 931-935 | Received 08 May 2018, Accepted 23 Jul 2018, Published online: 31 Jul 2018

References

  • Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41:545–568.
  • Coates LC, FitzGerald O, Merola JF, et al. Group for research and assessment of psoriasis and psoriatic arthritis/outcome measures in rheumatology consensus-based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis. Arthritis Rheumatol. 2018;70:345–355.
  • Gossec L, Coates LC, de Wit M, et al. Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. Nat Rev Rheumatol. 2016;12:743–750.
  • Roberts J, O’Rielly DD, Rahman P. A review of ustekinumab in the treatment of psoriatic arthritis. Immunotherapy. 2018;10:361–372.
  • Asahina A, Umezawa Y, Momose M, et al. New onset or transition of disease state of psoriatic arthritis during treatment with ustekinumab: A single-center retrospective study. J Dermatol. 2017;44:1380–1384.
  • Napolitano M, Balato N, Caso F, et al. Paradoxical onset of psoriatic arthritis during treatment with biologic agents for plaque psoriasis: a combined dermatology and rheumatology clinical study. Clin Exp Rheumatol. 2017;35:137–140.
  • Song GG, Lee YH. Relative efficacy and safety of apremilast, secukinumab, and ustekinumab for the treatment of psoriatic arthritis. Z Rheumatol. 2017 Aug 8. DOI:10.1007/s00393-017-0355-8.
  • Kawalec P, Holko P, Moćko P, et al. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis. Rheumatol Int. 2018;38:189–201.
  • Balsa A, Lula S, Marshall L, et al. The comparative immunogenicity of biologic therapy and its clinical relevance in psoriatic arthritis: a systematic review of the literature [abstract]. Arthritis Rheumatol. 2016;68(suppl):10.
  • Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30:1148–1158.
  • Michelsen B, Diamantopoulos AP, Høiberg HK, et al. Need for improvement in current treatment of psoriatic arthritis: study of an outpatient clinic population. J Rheumatol. 2017;44:431–436.
  • Napolitano M, Costa L, Caso F, et al. Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study. Clin Rheumatol. 2017;36:1589–1593.
  • Almirall M, Rodriguez J, Mateo L, et al. Treatment with ustekinumab in a Spanish cohort of patients with psoriasis and psoriatic arthritis in daily clinical practice. Clin Rheumatol. 2017;36:439–443.
  • Iannone F, Santo L, Bucci R, et al. Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. real-life data from the biologic apulian registry (BIOPURE). Clin Rheumatol. 2018;37:667–675.
  • Chimenti MS, Ortolan A, Lorenzin M, et al. Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study. Clin Rheumatol. 2018;37:397–405.
  • Queiro R, Brandy A, Rosado MC, et al. Minimal disease activity and patient-acceptable symptom state in psoriatic arthritis: a real-world evidence study with ustekinumab. J Clin Rheumatol. 2018 Mar 6. DOI:10.1097/RHU.0000000000000751.
  • Queiro R, Cañete JD, Montilla C, et al. Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study. Arthritis Res Ther. 2017 29;19(1):72.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.